Rhode Island is currently home to 506 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Providence, Warwick, East Providence and Johnston. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
NCT04970901
Recruiting
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin, glofitamab, or mosunetuzumab, and to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) for the combinations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Brown University Health - Rhode Island Hospital, Providence, Rhode Island
Conditions: B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
Register for Updates
Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
NCT04543071
Recruiting
The purpose of this study is to determine if combination treatment with cemiplimab, motixafortide, gemcitabine, and nab-paclitaxel is effective in decreasing the size of the tumor(s), if it will prolong life in patients, and if it's safe. The treatment consists of standard chemotherapy (gemcitabine and nab-paclitaxel) which is FDA approved and is standard treatment for patients with pancreatic adenocarcinoma. Participants will receive immunotherapy (cemiplimab) which activates the body's immune... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Brown University, Providence, Rhode Island
Conditions: Pancreatic Cancer, Adenocarcinoma of the Pancreas, Adenocarcinoma
Register for Updates
Rhode Island - Statewide Postpartum Hypertension Remote Surveillance
NCT06842875
Recruiting
This is a hybrid type 1 non-inferiority implementation effectiveness trial among postpartum patients with hypertension (N=1536) that will test the hypothesis that RI-SPHERES (a technologically enabled collaborative care model) is non-inferior to a standard self-measured blood pressure program in terms of persistent hypertension at six weeks postpartum and preventive care receipt within one year of delivery.
Gender:
FEMALE
Ages:
Between 18 years and 60 years
Trial Updated:
06/12/2025
Locations: Newport Hospital, Newport, Rhode Island
Conditions: Hypertension in Pregnancy, Postpartum Preeclampsia, Postpartum Complication
Register for Updates
A Study of Mosliciguat in PH-ILD
NCT06635850
Recruiting
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/11/2025
Locations: Brown Medicine, East Providence, Rhode Island
Conditions: Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Register for Updates
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
NCT06401421
Recruiting
The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis. Participants will be followed for up to 5.5 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: Women & Infants Hospital, Providence, Rhode Island
Conditions: Breast Cancer
Register for Updates
Mobile Peer Support for OUD Recovery
NCT05405712
Recruiting
The COVID-19 pandemic puts individuals recovering from opioid use disorders (OUDs), an already vulnerable population, at increased risk of overdose due to decreased access to treatment, decreased social support, and increased psychosocial stress. This proposal will test the efficacy of a promising mobile app-based peer support program, compared to usual care, in increasing recovery capital, improving retention in treatment, and reducing psychosocial adverse effects, among a national sample of pe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: Brown University School of Public Health, Providence, Rhode Island
Conditions: Opioid Use Disorder
Register for Updates
A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS
NCT05277168
Recruiting
The study (dose escalation/expansion) is being conducted to assess the safety and tolerability of SHR-A1904 in subjects with advanced solid tumors, and to determine maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D), to assess preliminary efficacy of SHR-A1904, pharmacokinetic (PK) profile and immunogenicity of SHR-A1904 in subjects with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: Rhode Island Hospital, Providence, Rhode Island
Conditions: Advanced Solid Tumors
Register for Updates
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
NCT07011667
Recruiting
This study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term. The study has 2 parts: The first part is called 'the main study' and the second part is called 'the extension study'. In the main study participants will either get CagriSema (a study medicine) or placebo (a dummy medicine that looks like CagriSema but has no active ingredient). Which treatment participants get is decided by chance. Participants are two times more li... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2025
Locations: Clinical Res Collaborative, Cumberland, Rhode Island
Conditions: Obesity
Register for Updates
RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight
NCT06987513
Recruiting
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in the treatment of AUD in subjects with obesity or overweight. After signing the informed consent form, subjects will be screened and if eligible randomized 1:1 to 1 of the following 2 treatment arms: * Pemvidutide: 2.4 mg SC once weekly * Placebo: Placebo SC once weekly
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/10/2025
Locations: Altimmune Clinical Study Site, Providence, Rhode Island
Conditions: Alcohol Use Disorder (AUD)
Register for Updates
POMEGRANATE Trial: Comparing Reia Pessary Versus Standard of Care Pessary for Pelvic Organ Prolapse Treatment
NCT06634459
Recruiting
This multi-centered, randomized controlled trial will evaluate the safety and efficacy of home use of the novel Reia System (RS), which includes the Reia pessary and applicator, compared to standard pessary care (Gellhorn or ring with/without support without knob) among women with stage II-IV pelvic organ prolapse (POP). A total of 182 participants will be recruited among pessary naïve patients who are symptomatic and choose a vaginal pessary for management of their POP from study sites speciali... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/10/2025
Locations: Women & Infants Hospital in Rhode Island, Providence, Rhode Island
Conditions: Pelvic Organ Prolapse, Prolapse
Register for Updates
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
NCT06254950
Recruiting
The main aim of this study is to learn if TAK-279 reduces bowel inflammation and symptoms compared to placebo. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate any problems. The participants will take capsules of either TAK-279 or placebo for up to 3 months (12 weeks). Then all the participants will receive TAK-279 for the rest of the treatment part of the study (1 year or 52 weeks). During the study,... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/10/2025
Locations: University Gastroenterology, Providence, Rhode Island
Conditions: Ulcerative Colitis
Register for Updates
Beat Childhood Cancer Specimen Banking and Data Registry
NCT04715178
Recruiting
This is an observational data registry study of pediatric cancer patients at participating Beat Childhood Cancer Consortium sites involving specimen banking and data collection.
Gender:
ALL
Ages:
All
Trial Updated:
06/10/2025
Locations: Hasbro Children's Hospital, Providence, Rhode Island
Conditions: Pediatric Cancer, Survivorship
Register for Updates